配售及认购完成后，卖方公司控股股东富域香港投资持股比例由64.78%轻微摊薄至63.01%。董事会表 示，配售及认购事项有助扩大股东及资本基础，增强财务灵活性，符合公司及股东整体利益。 智通财经APP获悉，新城发展(01030)低开近7%，截至发稿，跌6.76%，报2.62港元，成交额4.75亿港 元。 消息面上，新城发展公布，以先旧后新向不少于六名买方配售1.98亿股股份，占扩大后已发行股本约 2.73%，每股配售价为2.39港元，较2月4日收市价2.81港元折让14.95%，集资总额及净额各约4.73亿港元 及4.68亿港元，将用于公司未来发展及偿还到期债务及作一般营运资金等。 ...

Group 1 - OSL Group (00863) announced a placement and subscription agreement on January 28, 2026, where the seller, Crown Research Investments Limited, agreed to sell shares at a placement price of HKD 14.90 per share, which represents a discount of approximately 17.2% from the last trading price of HKD 18.00 per share [1] - The placement shares amount to 105 million shares, which represents about 13.2% of the company's existing issued share capital as of the announcement date and approximately 11.6% of the enlarged issued share capital after the completion of the subscription [1] Group 2 - The total amount expected from the subscription is approximately HKD 1.56 billion, with a net amount estimated at around HKD 1.55 billion after deducting all related costs and expenses associated with the placement and subscription [2]

Core Viewpoint - The company, YouRan Agriculture (09858.HK), has entered into a placement and subscription agreement to issue approximately 299 million shares at a price of HKD 3.92 per share, which represents an 8.84% discount to the last closing price of HKD 4.30 [1][2]. Group 1: Placement and Subscription Agreement - The placement agent, Morgan Stanley and CITIC Securities, has agreed to facilitate the purchase of the placement shares by at least six subscribers [1]. - The estimated net proceeds from the placement are expected to be approximately HKD 11.59 billion [1]. - The placement shares represent about 7.69% of the company's existing issued share capital as of the announcement date [1][2]. Group 2: Special Authorization Subscription - The company has entered into a special authorization subscription agreement with the seller, which allows the seller to subscribe for approximately 299 million new shares at the same price of HKD 3.92 per share [2]. - The estimated net proceeds from the special authorization subscription are expected to be approximately HKD 11.72 billion [2]. - The number of special authorization subscription shares also represents about 7.69% of the company's existing issued share capital as of the announcement date [2]. Group 3: Completion of Transactions - The placement has been completed as of January 20, 2026, with the placement agent successfully placing the shares to independent third-party subscribers [2]. - Following the completion of the placement and special authorization subscription, the seller's shareholding in the company remains unchanged [3].

Group 1 - Nanshan Aluminum International's stock fell over 5%, specifically by 5.37%, trading at 65.2 HKD with a transaction volume of 2.039 billion HKD [1] - The company announced a placement of 31 million shares, representing approximately 5% of the enlarged share capital, at a price of 64.5 HKD per share, which is a discount of about 6.39% compared to the closing price of 68.9 HKD on January 21 [1] - If the subscription is fully placed, the total amount expected from the subscription is approximately 1.9995 billion HKD, with a net amount of about 1.9868 billion HKD, of which around 90% will be used for potential electrolytic aluminum and related raw materials and auxiliary businesses, while 10% will be allocated for general working capital [1]

Core Viewpoint - The company, YouRan Agriculture (09858), has announced a share placement and subscription agreement, aiming to raise approximately HKD 11.59 billion through the issuance of new shares at a price of HKD 3.92 per share, which represents an 8.84% discount compared to the last closing price of HKD 4.30 [1][2] Group 1 - The share placement involves the sale of shares by the seller, BoYuan, with the placement agent facilitating the purchase of at least six subscribers at the specified price [1] - The company will issue new shares under a general authorization at the same price of HKD 3.92 per share, matching the number of shares sold by the placement agent [1] - The total number of new shares to be issued under the special authorization subscription agreement is 299 million, which will account for approximately 7.14% of the enlarged issued share capital after the placement [2] Group 2 - The estimated net proceeds from the placement and subscription are expected to be approximately HKD 11.59 billion and HKD 11.72 billion, respectively [2] - The funds raised will be utilized for advanced technology empowerment and digital transformation to enhance operational efficiency, debt repayment, and to provide flexibility for potential acquisitions or investments [2] - The placement price of HKD 3.92 per share reflects an 8.84% discount to the last trading price, indicating a strategic pricing decision to attract investors [2]

Core Viewpoint - The company, YouRan Agriculture (09858), has entered into a placement and subscription agreement to issue new shares at a price of HKD 3.92 per share, which represents an approximate discount of 8.84% compared to the last closing price of HKD 4.30 per share [1][2] Group 1: Share Issuance Details - The company will issue 299 million new shares under the special authorization subscription agreement, which will account for approximately 7.14% of the enlarged issued share capital after the placement and subscription [2] - The estimated net proceeds from the placement and subscription are expected to be approximately HKD 11.72 billion [2] Group 2: Use of Proceeds - The net proceeds from the placement and subscription will be utilized for advanced technology empowerment and digital transformation to enhance operational efficiency, repayment of interest-bearing debts to optimize capital structure, and to supplement working capital for general corporate purposes [2]

Core Viewpoint - China Hongqiao (01378.HK) has experienced significant volatility, with its stock price more than doubling earlier this year, reaching a market capitalization of over 300 billion HKD, but recently faced a sharp decline due to a planned share placement [1] Group 1: Stock Performance - China Hongqiao's stock hit a record high of 35.1 HKD but subsequently dropped nearly 4% the following day, with a cumulative decline of nearly 15% from its peak [1] - The trading volume surged to 17 billion HKD, indicating substantial selling pressure [1] Group 2: Share Placement Announcement - The immediate cause of the stock decline was the announcement of a placement of 400 million shares, expected to raise up to 11.49 billion HKD [1] - The placement price is set at 29.2 HKD, representing a discount of approximately 9.6% compared to the previous closing price of 32.3 HKD [1] Group 3: Placement Mechanism - The share placement follows a "old shares first, new shares later" approach, where major shareholders first sell their existing shares to independent investors [2] - The company will then issue new shares to the major shareholders to restore their ownership levels [4] - This method allows for quicker financing compared to traditional new share issuance, balancing efficiency and market acceptance [4] Group 4: Market Implications - While the placement facilitates rapid fundraising, the significant discount on the placement price and the resulting dilution of existing shareholders' stakes may negatively impact the stock price in the short term [4] - The long-term effects will depend on how effectively the raised funds are utilized to enhance the company's operations [4]

Core Viewpoint - The company, Heng Tai (00197), has announced a placement and subscription agreement involving the issuance of 30.606 million shares at a price of HKD 0.476 per share, which represents a discount of approximately 17.93% compared to the closing price of HKD 0.580 on October 8 [1] Group 1 - The placement agent has agreed to facilitate the purchase of at least six subscribers for the placement shares [1] - The total number of subscription shares represents about 17.14% of the company's existing share capital as of the announcement date [1] - The maximum total amount raised from the subscription is estimated to be approximately HKD 14.6 million, with a net amount of about HKD 14.2 million [2] Group 2 - The net proceeds from the subscription will be used for renovations of the logistics center in Shanghai, upgrading furniture and logistics equipment, purchasing new equipment, expanding the workforce at the Dongguan processing center, and general working capital [2]

Core Viewpoint - The company, Heng Tai (00197), has announced a share placement and subscription agreement, which involves the issuance of 30.606 million shares at a price of HKD 0.476 per share, representing a discount of approximately 17.93% from the closing price on October 8, 2023 [1] Summary by Relevant Sections Share Placement and Subscription - The placement agent has agreed to act on behalf of the subscriber to facilitate the purchase of at least six subscribers for the placement shares at HKD 0.476 per share, totaling 30.606 million shares [1] - The subscriber, who is the company's chairman and CEO, has conditionally agreed to subscribe for the shares, and the company has conditionally agreed to issue the subscription shares [1] Financial Implications - The maximum total amount raised from the subscription is expected to be approximately HKD 14.6 million, with a net amount of about HKD 14.2 million [1] - The subscription shares represent approximately 17.14% of the company's existing share capital as of the announcement date, and approximately 14.63% of the enlarged issued share capital post-placement [1] Use of Proceeds - The net proceeds from the subscription will be used for the renovation of the logistics center in Shanghai, upgrading furniture and logistics equipment, purchasing new equipment, expanding the workforce at the Dongguan processing center, and general working capital for the group [1]

Core Viewpoint - The company, Xiansheng Pharmaceutical (02096.HK), has entered into a placement and subscription agreement to issue 121 million shares at a price of HKD 12.95 per share, which represents an approximate 8.03% discount from the last closing price of HKD 14.08 [1][2]. Group 1: Placement and Subscription Details - The seller, Simcere Pharmaceutical Holding Limited, holds approximately 938 million shares, accounting for about 37.92% of the company's total issued shares [2]. - The total estimated gross proceeds from the subscription are approximately HKD 1.567 billion, with a net amount of about HKD 1.554 billion expected to be received by the company [2]. - The placement shares represent about 4.89% of the company's total issued shares as of the announcement date, and the enlarged total issued shares after the placement will be approximately 4.66% [1]. Group 2: Use of Proceeds - Approximately 90% of the net proceeds will be allocated to research and development expenses, which include accelerating clinical research for new drugs in China and the U.S., and supporting the expansion of approved innovative drugs into new indications [2]. - The remaining 10% of the net proceeds will be used for working capital and other general corporate purposes to support the company's daily operations and long-term development needs [2].